A retrospective study of immune-related ophthalmic side effects of systemic checkpoint inhibitors and compare side effect frequency and requirement for cessation of immunotherapy by checkpoint target
Latest Information Update: 15 Oct 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Blepharoptosis; Diplopia; Dry eyes; Ocular inflammation; Uveitis
- Focus Adverse reactions
- 15 Oct 2021 New trial record
- 01 Sep 2021 Results published in the British Journal of Ophthalmology